Article
Phage and Yeast Display
27 Feb 2015
Abstract excerpt
Despite the availability of antimicrobial drugs, the continued development of microbial resistance--established through escape mutations and the emergence of resistant strains--limits their clinical utility. The discovery of novel, therapeutic, monoclonal antibodies (mAbs) offers viable clinical alternatives in the treatment and prophylaxis of infectious diseases. Human mAb-based therapies are typically nontoxic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
